Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.49

+3.7%

10:19 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (7254)	10/28/2002 6:57:34 PM
From: Miljenko Zuanic	of 52153

Rituxan results (for 24 weeks) are in line with Enbrel, very good. However pts selection (from concern about side effects) and additional drug (corticosteroids, which are regular in Rituxan administration, BTW at 50mg/hr this was 20 hr infusion) may influence results, maybe even significantly. Nonetheless, it will be very interesting to do Rituxan clinical trials for those who relapsed on anti-TNF therapy, or non-responder. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next